Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Renalytix plc is a healthcare technology company focused on transforming kidney disease management through its innovative KidneyIntelX platform. Its flagship product, kidneyintelX.dkd, is an FDA-authorized prognostic test that assesses the risk of kidney function decline in adults with diabetes. Targeting a market of approximately 14 million U.S. patients, Renalytix aims to improve patient outcomes and reduce healthcare costs through early intervention and comprehensive insurance coverage initiatives.
This description was generated via AI from an annual report. Updated about 1 year ago.